Biology subjects

Kahn, J.

Publications and source records attributed to Kahn, J..

4 recordsLinked to original sources

bioRxiv2026

Bone Morphogenetic Protein Pathway Modulates Parkinson's Disease Genetic Risk and Promotes Motor Recovery

Progress toward disease-modifying Parkinsons disease (PD) therapies is hindered by limited understanding of pathogenic drivers and lack of therapies that restore the damaged dopaminergic (DA) neurons driving motor deficits. We investigated the role of the bone morphogenetic protein (BMP) pathway in PD using common and rare genetic variants across large-scale datasets. Single-variant analyses identified nominal associations with PD risk and onset age. A BMP polygenic risk score (PRS) was significantly associated with PD risk (OR = 1.21, empirical P = 1.0 x 10-), a result replicated in proxy-case analyses (OR = 1.14, empirical P = 1.0 x 10-) and remained significant after sensitivity testing. To test the results functional relevance, we genetically and pharmacologically inhibited BMP signaling in mice, which induced motor deficits and PD-like neuropathology. In a -synuclein preformed fibril (PFF) mouse model, BMP5 and BMP7 (BMP5/7) demonstrated neuroprotective effects when administered concurrently with -synuclein PFFs. Importantly, when delivered after PFFs-induced motor symptoms onset, BMP5/7 demonstrated neurorestorative effects, ameliorating both motor impairments and neuropathology. These findings provide first evidence that BMP signaling variations contribute to polygenic PD risk, identify a physiological role for this pathway in safeguarding against PD-related pathology, and demonstrate BMPs therapeutic potential for disease modification.

neuroscience↗

bioRxiv2026

Intermediate Relative Humidity Preserves Respiratory Syncytial Virus via a Semi-Solid Bioaerosol State

Respiratory syncytial virus (RSV) transmission via the aerosol route remains poorly understood, particularly with respect to how evolving virus-laden particles (bioaerosols) microenvironments influence viral survival. Bioaerosol particles contain complex mixtures of organic and inorganic components, and their physicochemical properties change dynamically during evaporation as water is lost upon emission from respiratory activities. These changes directly affect the local environment surrounding embedded virus during both the evaporation stage and the subsequent equilibrium state. However, how these microenvironmental conditions under different relative humidity (RH) levels regulate RSV survival remains unclear. In this study, we quantified RSV survival during the evaporation and early equilibrium stages using a flow-tube system with controlled residence times. Bioaerosols were generated from virus medium alone or supplemented with bovine serum albumin (BSA) or mucin and evaluated under low (35%) and intermediate (61%) RH conditions. Viral infectivity was normalized to RNA copy number to account for particle and sampling losses. At 35% RH, RSV infectivity decreased by one to three orders of magnitude, depending on the solution composition. In contrast, survival was significantly higher at intermediate RH, particularly for virus medium and BSA-supplemented aerosols. Scanning electron microscopy revealed that low RH conditions promote efflorescence, whereas intermediate RH results in viscous or semi-solid particles with higher water content. These observations suggest that efflorescence is associated with enhanced RSV inactivation, while viscous or semi-solid phases tend to preserve RSV in the aerosol state for respirable particles. Overall, RSV infectivity depends strongly on particle chemical composition, phase state (effloresced versus semi-solid), and relative humidity. These results highlight the importance of characterizing particle phase behavior and chemical composition during early aerosol processes to improve mechanistic understanding of viral survival relevant to short-range transmission.

microbiology↗

bioRxiv2025

A wireless, 60-channel, AI-enabled neurostimulation platform

ObjectiveClosed-loop neuromodulatory therapies require devices that can both decode ongoing brain states and deliver multi-site stimulation. MethodsWe describe the Smart Neurostimulation System (SNS), a cranially mounted implant with 60 configurable recording/stimulation channels, inductive power, and onboard spectral-feature classification. In three freely-moving sheep we streamed local-field potentials and conducted two parameter sweep experiments. ResultsCross-validated movement classifiers achieved an average AUC > 0.95. Increasing stimulation amplitude and frequency produced post-stimulation elevations in -band (8-12 Hz) and{gamma} -band (78-82 Hz) power at most target locations. ConclusionThe SNS unifies high-density sensing, real-time brain state decoding, and programmable closed-loop stimulation in a single device, demonstrating behavioral-state prediction and parameter-dependent neuromodulation in vivo. SignificanceThese findings establish a preclinical foundation for biomarker-guided stimulation targeting distributed cortical networks underlying memory and cognition. HighlightsO_LIWireless 60-channel implant enables simultaneous sensing and stimulation C_LIO_LIvine study demonstrates reliable classification of movement and stimulation-related modulation of spectral activity C_LIO_LIThe SNS represents a platform for biomarker-guided neuromodulation therapies C_LI

neuroscience↗

bioRxiv2024

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform

Protein phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D), is a serine/threonine phosphatase that is recurrently activated in cancer, regulates the DNA damage response (DDR), and suppresses the activation of p53. Consistent with its oncogenic properties, genetic loss or pharmacologic inhibition of PPM1D impairs tumor growth and sensitizes cancer cells to cytotoxic therapies in a wide range of preclinical models. Given the therapeutic potential of targeting PPM1D specifically and the DDR and p53 pathway more generally, we sought to deepen our biological understanding of PPM1D as a drug target and determine how PPM1D inhibition differs from other therapeutic approaches to activate the DDR. We performed a high throughput screen to identify new allosteric inhibitors of PPM1D, then generated and optimized a suite of enzymatic, cell-based, and in vivo pharmacokinetic and pharmacodynamic assays to drive medicinal chemistry efforts and to further interrogate the biology of PPM1D. Importantly, this drug discovery platform can be readily adapted to broadly study the DDR and p53. We identified compounds distinct from previously reported allosteric inhibitors and showed in vivo on-target activity. Our data suggest that the biological effects of inhibiting PPM1D are distinct from inhibitors of the MDM2-p53 interaction and standard cytotoxic chemotherapies. These differences also highlight the potential therapeutic contexts in which targeting PPM1D would be most valuable. Therefore, our studies have identified a series of new PPM1D inhibitors, generated a suite of in vitro and in vivo assays that can be broadly used to interrogate the DDR, and provided important new insights into PPM1D as a drug target.

cancer biology↗